Open Orphan (hVIVO) is a leader in human respiratory disease and infectious disease challenge clinical studies. It has reported in the H1FY22 results revenues of £18.9mln in the first six months of the year at an EBITDA margin of 12.1%. EBITDA was £2.3mln for the period.